CHALLENGING POST-TRANSPLANT COURSE AND MULTIORGAN COMPLICATIONS IN FLT3-POSITIVE ACUTE MYELOID LEUKEMIA
Academic Medical Journal · 18.06.2026 · 6 (2) · 131-138
DOI: 10.53582/1kedyf46 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academic Medical Journal, online erschienen am 18.06.2026. Verfasst von Tara Mojsovska und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
FLT3-mutated acute myeloid leukemia (AML) represents a biologically aggressive subtype associated with high relapse rates and poor overall survival. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most effective curative therapy, yet it carries substantial risk of transplant-related morbidity and mortality. Case report: We report the case of a 42-year-old woman diagnosed with FLT3-ITD positive AML who underwent several chemotherapy regimens and achieved complete molecular remission prior to a matched unrelated donor allo-HSCT (9/10, MM in HLA-A). Following myeloablative conditioning (BuCy-ATG), engraftment occurred by day +19. The post-transplant course was complicated by cytomegalovirus (CMV) reactivation (day +28), acute graft-versus-host disease (aGvHD) with severe cutaneous and gastrointestinal involvement (day +31), and transplant-associated thrombotic microangiopathy (TA-TMA) accompanied by hemolysis, thrombocytopenia, and hyperbilirubinemia (day +40). Subsequent neurologic deterioration revealed posterior reversible encephalopathy syndrome (PRES) related to calcineurin-inhibitor toxicity. Despite combined therapy including corticosteroids, plasmapheresis, rituximab, and antiviral treatment, multiorgan dysfunction developed, culminating in fatal cardiorespiratory failure on day +99 post-transplant.
Conclusions
This case underscores the extreme clinical complexity of post-transplant management in FLT3+ AML. The sequential onset of immune-mediated, endothelial, infectious, and neurologic complications highlights the necessity for vigilant monitoring, early diagnostic work-up, and coordinated multidisciplinary care. Proactive risk stratification and individualized prophylactic approaches remain essential to improve survival after allo-HSCT in high-risk AML.
Zitieren
APA
Mojsovska, T., Ridova, N., Janev, O. G., Purde, M., Stojanoski, M., Chadievski, L., Stojanoski, Z., Balkanov, S. K., Stavridis, I. P., Pavkovikj, M., Stavrikj, S. G., & Veljanovska, A. P. (2026). CHALLENGING POST-TRANSPLANT COURSE AND MULTIORGAN COMPLICATIONS IN FLT3-POSITIVE ACUTE MYELOID LEUKEMIA. Academic Medical Journal, 6(2), 131-138. https://doi.org/10.53582/1kedyf46
Vancouver
Mojsovska T, Ridova N, Janev OG, Purde M, Stojanoski M, Chadievski L, et al. CHALLENGING POST-TRANSPLANT COURSE AND MULTIORGAN COMPLICATIONS IN FLT3-POSITIVE ACUTE MYELOID LEUKEMIA. Academic Medical Journal. 2026;6(2):131-138. doi:10.53582/1kedyf46
BibTeX
@article{Mojsovska2026,
author = {Mojsovska, Tara and Ridova, Nevenka and Janev, Olivera Gjeorgjieva and Purde, Merve and Stojanoski, Martin and Chadievski, Lazar and Stojanoski, Zlate and Balkanov, Svetlana Krstevska and Stavridis, Irina Panovska and Pavkovikj, Marica and Stavrikj, Sonja Genadieva and Veljanovska, Aleksandra Pivkova},
title = {CHALLENGING POST-TRANSPLANT COURSE AND MULTIORGAN COMPLICATIONS IN FLT3-POSITIVE ACUTE MYELOID LEUKEMIA},
journal = {Academic Medical Journal},
year = {2026},
volume = {6},
number = {2},
pages = {131--138},
doi = {10.53582/1kedyf46}
}
EUVIMED